August 03, 2022
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
June 28, 2022
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
June 23, 2022
Stop of treatment in COVID-19 study
June 14, 2022
Option to Acquire Trutino Biosciences
June 02, 2022
A*STAR antibodies bolster ADC and T-Cell engager development
May 15, 2022
Investigational treatment slowed lung function decline in IPF
May 12, 2022
TwistPak®: Mixing platform for swine vaccines brings convenience and flexibility
May 11, 2022
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
April 05, 2022
Good business performance gives Boehringer Ingelheim tailwind for investment in Research and Development
March 28, 2022
New spesolimab data show significant improvement in GPP flares
March 28, 2022
New spesolimab data show clinically significant improvement in GPP flares
媒体联系人
公司通信和公共事务部主管
集团沟通部负责人
Head of Human Pharma Communications
E-Mail:
anthonia.aboyeji@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-172370
Head of Global Communications AH
E-Mail:
Heidi.DeWit-Sommerfeld@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-171799